Drug intelligence / Profile preview

alpha-type-1-polarized dendritic cell vaccine

Development stage: Phase 2
Lead developer: Roswell Park Comprehensive Cancer Center
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

The alpha-type-1-polarized dendritic cell vaccine (αDC1) is an autologous cell-based cancer immunotherapy developed by Dr. Pawel Kalinski and colleagues. This vaccine consists of dendritic cells generated from a patient's own peripheral blood mononuclear cells and matured using a specialized cytokine cocktail containing IFN-alpha, polyinosinic:polycytidylic acid (poly-I:C), TNF-alpha, IL-1beta, and IFN-gamma. The αDC1 cells are characterized by three key features: a fully mature status, responsiveness to secondary lymphoid organ chemokines (CCR7 ligands), and high interleukin-12p70 (IL-12p70) production capacity. These dendritic cells are loaded with tumor-associated antigens, such as apoptotic autologous tumor cells, and administered to patients to induce potent cytotoxic T lymphocyte (CTL) responses. The vaccine aims to stimulate the patient's immune system to recognize and destroy tumor cells by promoting Type-1 immunity and enhancing CTL infiltration into tumor tissues.

Other names: alpha-type-1 dendritic cell vaccinealpha-type1 dendritic cell vaccinealpha-type 1 dendritic cell vaccineαDC1 vaccineautologous alpha-type-1-polarized dendritic cell vaccine

Beyond the preview

Go deeper on alpha-type-1-polarized dendritic cell vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-type-1-polarized dendritic cell vaccine.

Explore the full profile